Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04515472 · ClinicalTrials.gov registry record · Early Phase 1
Effect of Gender Affirming Hormone Therapy on Glucose Metabolism
A Early Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
NCT04515472 is a Early Phase 1 study that was terminated before completion, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 24 participants.
The verdict
NCT04515472, a Early Phase 1 study, was terminated before completion, sponsored by The University of Texas Health Science Center at San Antonio.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The study will test: 1. whether estrogen treatment in transwomen is associated with improved insulin sensitivity and beta cell function 2. whether testosterone treatment in transmen is associated with worsening insulin sensitivity and beta cell function 3. whether estrogen therapy leads to enhanced immune response in older transwormen
Interventions
- DRUG Botnia Clamp
- OTHER Withdrawal of Gender Affirming Hormone Therapy (GAHT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-06-17 |
| Est. Completion | 2025-03-17 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04515472
The ClinicalTrials.gov registry entry for NCT04515472 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Botnia Clamp is the first listed.
NCT04515472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04515472 about?
NCT04515472 is a clinical study titled "Effect of Gender Affirming Hormone Therapy on Glucose Metabolism". The study will test: 1. whether estrogen treatment in transwomen is associated with improved insulin sensitivity and beta cell function 2. whether testosterone treatment in transmen is associated with worsening insulin sensitivity and beta cell function 3. whether estrogen therapy leads to enhanced...
What is the current status of trial NCT04515472?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2020-06-17. Estimated completion is 2025-03-17.
What interventions are being tested in trial NCT04515472?
The interventions under investigation include: Botnia Clamp (DRUG), Withdrawal of Gender Affirming Hormone Therapy (GAHT) (OTHER).
Who is sponsoring clinical trial NCT04515472?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.